MissionIR News - International Stem Cell Corp. (ISCO) to Present Comprehensive Findings for Parkinson’s Disease Program Preclinical Studies at Society for Neuroscience Annual Meeting

MissionIR would like to highlight International Stem Cell Corporation (OTCBB: ISCO), researching the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). The company is focused on using these stem cells to treat diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells or tissue.

In the company’s news,

International Stem Cell Corp. said it will make an oral presentation on the comprehensive results of its preclinical development of human parthenogenetic neural stem cells (hPNSCs) for the treatment of Parkinson’s Disease at the upcoming Neuroscience 2015 in Chicago.

The session, entitled, “Therapeutics of Parkinson’s Disease: Preclinical Studies,” will take place October 20 from 8 a.m.-10:15 a.m. ET.

“The comprehensive data collected from our extensive GLP studies serve as proof of safety and efficacy for our planned clinical trial for the treatment of Parkinson’s Disease in Australia. We look forward to providing an update on the status of our regulatory submission to the Australian government in the near future,” Russell A. Kern, Ph.D. chief scientific officer of ISCO, stated in the news release.

ISCO’s Parkinson’s disease program uses human parthenogenetic neural stem cells (hPNSC), which are a novel therapeutic cellular product derived from ISCO’s proprietary human pluripotent stem cells. hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to differentiate into dopaminergic neurons and express neurotrophic factors to protect the nigrostriatal system offers a new opportunity for the treatment of Parkinson’s disease.

ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.